文献速递肿瘤 PET/CT神经核医学

68Ga-DOTATATE PET/CT计算的生长抑素受体表达肿瘤体积在高分化神经内分泌肿瘤中的预后价值

Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-07-27

单因素分析显示WHO肿瘤分级和ΣSRETV与无进展生存期(PFS)显著相关(P<0.05),多因素分析确定WHO分级和ΣSRETV为PFS的独立预测因素。结论提示ΣSRETV可能对WD-NET患者的PFS具有预后价值。

要点

  • WHO肿瘤分级和ΣSRETV与WD-NET患者PFS显著相关。
  • ΣSRETV是PFS的独立预测因素,而SUVmax和ΣTLSRE未显示显著预后价值。
  • 基于68Ga-DOTATATE PET/CT的体积参数可能辅助WD-NET风险分层。

核心结论

  • 基于68Ga-DOTATATE PET/CT计算的ΣSRETV可能对高分化神经内分泌肿瘤患者的无进展生存期具有预后价值。

研究设计与样本

  • 每例患者测量最高68Ga-DOTATATE摄取病灶的SUVmax,并计算每个摄取病灶的SRETV和TLSRE,以及每例患者所有病灶的ΣSRETV和ΣTLSRE。
  • 以无进展生存期(PFS)为主要终点,采用Kaplan-Meier生存分析、log-rank检验和Cox比例风险模型进行统计分析。

主要发现

  • 单因素分析显示WHO肿瘤分级和ΣSRETV对PFS有显著差异(P<0.05)。
  • 年龄、性别、SUVmax和ΣTLSRE对PFS无显著差异(P>0.05)。
  • 多因素分析确定WHO肿瘤分级和ΣSRETV为PFS的独立预测因素。

关键数值与推荐

  • SRETV定义为每个病灶感兴趣体积(VOI)内68Ga-DOTATATE摄取高于SUVmax 50%的肿瘤体积。
  • TLSRE通过SRETV与同一VOI内平均SUV相乘计算。
  • ΣSRETV和ΣTLSRE分别为每例患者所有检测病灶的SRETV和TLSRE之和。

临床怎么用

  • 对于高分化神经内分泌肿瘤患者,可考虑基于68Ga-DOTATATE PET/CT计算ΣSRETV以辅助预后评估。
  • WHO肿瘤分级和ΣSRETV可作为PFS的独立预测因素,用于风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the prognostic value of volumetric parameters calculated from 68Ga-1,4,7,10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA)-Thr3-octreotate (68Ga-DOTATATE) positron emission tomography/computed tomography (PET/CT) in patients with well-differentiated neuroendocrine tumor (WD-NET). METHODS: Ninety-two patients (44 men and 48 women, mean age of 59.5-year-old) with pathologically confirmed WD-NET (grades 1 or 2) were enrolled in a prospective expanded access protocol. Selected data was analyzed retrospectively for this project. Maximum standardized uptake value (SUVmax) in the lesion with the highest 68Ga-DOTATATE uptake was measured and recorded for each patient. In addition, two volumetric parameters, namely, somatostatin receptor expressing tumor volume (SRETV) and total lesion somatostatin receptor expression (TLSRE), were calculated in each 68Ga-DOTATATE-avid lesion. SRETV was defined as tumor volume with higher 68Ga-DOTATATE uptake than the 50% of SUVmax within the volume of interest (VOI) for each lesion. TLSRE was calculated by multiplying SRETV and mean SUV within the same VOI. Thereafter, the sum of SRETV (ΣSRETV) and TLSRE (ΣTLSRE) for all detected lesions per patient were calculated. Progression-free survival (PFS) was set as primary endpoint. Kaplan-Meier survival analysis, log-rank test, and Cox's proportional hazard model were used for statistical analysis. RESULTS: Univariate analyses revealed significant difference of PFS for WHO tumor grade and ΣSRETV (P < 0.05), while there were no significant differences in age, sex, SUVmax, and ΣTLSRE (P > 0.05). Multivariate analysis identified WHO tumor grade and ΣSRETV as independent predictors of PFS. CONCLUSION: ΣSRETV calculated from 68Ga-DOTATATE PET/CT may have prognostic value of PFS in WD-NET patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Toriihara A, Baratto L, Nobashi T, et al. Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019. PMID: 31350603. doi:10.1007/s00259-019-04455-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。